Epidemiology and Early Surgical Intervention in Necrotizing Fasciitis: A Retrospective Cohort Study in Japan
The Journal of Dermatology · 2025
DOI: 10.1111/1346-8138.17806 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Dermatology, 2025. Verfasst von Chieko Fujishima und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Fasciitis, Necrotizing, Time-to-Treatment, Debridement. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Although previous reports on necrotizing fasciitis have suggested that early initial surgery is associated with a better prognosis, the exact “golden time” for surgery remains undetermined. This single‐center, retrospective cohort study included patients with necrotizing fasciitis between December 2011 and December 2023. We described the features of necrotizing fasciitis and evaluated the association between early surgery, mortality, and amputation‐free survival in patients with necrotizing fasciitis. A total of 187 patients (median age: 65.5 years; 107 men and 82 women) were included in this study. The microbiological characteristics were generally consistent with those in previous reports from other countries, except for a low prevalence of methicillin resistance among Staphylococcus aureus , a high incidence of Group C or G Streptococci , and the scarcity of Vibrio vulnificus isolation. The mortality was lower in patients undergoing surgery within 0–6 h or 6–12 h compared with those after 12 h (14.6%, 16.1%, and 25.6%, respectively), with an adjusted odds ratio of 0.38 for 0–6 h (95% confidence interval 0.08–1.63) and 0.44 for 6–12 h (95% confidence interval 0.07–2.51). Furthermore, the mortality and/or amputation rate was significantly lower when the time to surgery was 0–6 h or 6–12 h compared with 12 h or more (adjusted odds ratio 0.19 for 0–6 h [95% confidence interval 0.05–0.62], and 0.23 for 6–12 h [95% confidence interval 0.05–0.90]). Our findings suggest that an early surgical intervention, particularly within 6 or 12 h after presentation, is associated with lower mortality and amputation rates in patients with necrotizing fasciitis, emphasizing the importance of prompt treatment for optimal outcomes. Further research is required to determine the optimal timing for surgery.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Kobe City Medical Center General Hospital, Kobe, Japan.
- Department of Emergency, Kobe City Medical Center General Hospital, Kobe, Japan.
- Department of Research Support, Center for Clinical Research and Innovation, Kobe City Medical Center General Hospital, Kobe, Japan.
- Department of Healthcare Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan.
- Department of Emergency Medicine, Akashi Medical Center, Akashi, Japan.
ORCID-Profile: Chieko Fujishima, Yoshinori Matsuoka, Hiroki Kinoshita, Tohru Nagano
Zitieren
APA
Fujishima, C., Matsuoka, Y., Kinoshita, H., Tanaka, R., Takeda, Y., Tai, Y., Ogura, K., Ariyoshi, K., & Nagano, T. (2025). Epidemiology and Early Surgical Intervention in Necrotizing Fasciitis: A Retrospective Cohort Study in Japan. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17806
Vancouver
Fujishima C, Matsuoka Y, Kinoshita H, Tanaka R, Takeda Y, Tai Y, et al. Epidemiology and Early Surgical Intervention in Necrotizing Fasciitis: A Retrospective Cohort Study in Japan. The Journal of Dermatology. 2025. doi:10.1111/1346-8138.17806
BibTeX
@article{Fujishima2025,
author = {Fujishima, Chieko and Matsuoka, Yoshinori and Kinoshita, Hiroki and Tanaka, Reina and Takeda, Yui and Tai, Yukimasa and Ogura, Kanako and Ariyoshi, Koichi and Nagano, Tohru},
title = {Epidemiology and Early Surgical Intervention in Necrotizing Fasciitis: A Retrospective Cohort Study in Japan},
journal = {The Journal of Dermatology},
year = {2025},
doi = {10.1111/1346-8138.17806}
}
EUVIMED